Backed by ARCH Venture Partners, F-Prime Capital and Mubadala Capital, the new company will develop a pipeline of ...

Tenvie Therapeutics has unveiled with $200 million and the goal of transforming the neurological treatment landscape, nabbing ...

"Tenvie was purpose-built to apply deep biological and chemical insights to address critical disease pathways,” said Paul L. Berns, Managing Director at ARCH Venture Partners and Executive Chair of ...

About a year ago, Tenvie President and Chief Scientific Officer Tony Estrada approached Denali CEO Ryan Watts and others in ...

Tenvie Therapeutics is making hay from an R&D shift at Denali Therapeutics, acquiring several of its neuroscience drug ...

Leyden Laboratories B.V. (the "Company" or "Leyden Labs") today announced it has raised $70M in funding to advance its ...

According to MoEngage’s Email Benchmark Report for 2025 and Beyond, personalized emails outperform the generic ones. The ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

The round was led by F-Prime Capital, with participation from Bienville Capital Management and Thayer Ventures. The investment will further TripSuite's mission to enhance the agency and traveler ...

Funding will propel Leyden Labs' non-vaccine intranasal antibody programs to safeguard people from respiratory viruses. The programs are based on Leyden Labs' Mucosal Protection Platform utilizing ...

The seed funding was led by F-Prime Capital. Also participating were Bienville Capital Management and Thayer Ventures. TripSuite co-founder and CEO Jacey Jones identified three main areas in which ...

Muzastotug is under clinical development by Adagene Suzhou and currently in Phase II for Metastatic Ovarian Cancer.